Hodgkin lymphoma : nature.com subject feeds
Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP
Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas
Conditional relative survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma in the Netherlands
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
CAR T cells are active in Hodgkin lymphoma
Hodgkin lymphoma
Can we cure refractory Hodgkin’s lymphoma with transplantation£
Tumor-associated macrophages in classical Hodgkin lymphoma: hormetic relationship to outcome
Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989–2017
Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT
Autologous hematopoietic cell transplantation for the treatment of relapsed/refractory pediatric, adolescent, and young adult Hodgkin lymphoma: a single institutional experience
PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma
Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities
Precise detection of genomic imbalances at single-cell resolution reveals intra-patient heterogeneity in Hodgkin’s lymphoma
Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment
Relationship between semiquantitative 18F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma
Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation
Body mass index and Hodgkin's lymphoma: UK population-based cohort study of 5.8 million individuals
A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma
Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility
Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma
The c-Jun and JunB transcription factors facilitate the transit of classical Hodgkin lymphoma tumour cells through G1
Nivolumab–induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin’s disease
Microgravity induces autophagy via mitochondrial dysfunction in human Hodgkin’s lymphoma cells
Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity
Feed Fetched by RSS Dog.